Functional links between gelatinase B/matrix metalloproteinase-9 and prominin-1/CD133 in diabetic retinal vasculopathy and neuropathy

Progress in Retinal and Eye Research

Volumn 43, Issue , 2014, Pages 76-91

  Mohammad, Ghulam ^a   Vandooren, Jennifer ^b   Siddiquei, Mohammad Mairaj ^a   Martens, Erik ^b   Abu El Asrar, Ahmed M ^a   Opdenakker, Ghislain ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Angiogenesis; Diabetes; Gelatinase B; Matrix metalloproteinase 9; Prominin 1 CD133; Retinopathy; Vasculogenesis

Indexed keywords

BETA ACTIN; CD133 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; GELATINASE A; GELATINASE B; OCCLUDIN; STROMAL CELL DERIVED FACTOR 1; VASCULAR CELL ADHESION MOLECULE 1; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE;

ARTICLE; BLOOD RETINA BARRIER; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; GENE INACTIVATION; HUMAN; NONHUMAN; PHOTORECEPTOR; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; DISEASE MODEL; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; GLYCOPROTEINS; HUMANS; MATRIX METALLOPROTEINASE 9; MICE; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES;

EID: 84908027802     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2014.07.002     Document Type: Article

References (106)

1. Abu El-Asrar A.M., Dralands L., Veckeneer M., Geboes K., Missotten L., Van Aelst I., Opdenakker G. Gelatinase B in proliferative vitreoretinal disorders. Am. J. Ophthalmol. 1998, 125:844-851.
2. Abu El-Asrar A.M., Mohammad G., Nawaz M.I., Siddiquei M.M., Van den Eynde K., Mousa A., De H.G., Opdenakker G. Relationship between vitreous levels of matrix metalloproteinases and vascular endothelial growth factor in proliferative diabetic retinopathy. PLoS One 2013, 8:e85857.
3. Abu El-Asrar A.M., Struyf S., Opdenakker G., Van Damme J., Geboes K. Expression of stem cell factor/c-kit signaling pathway components in diabetic fibrovascular epiretinal membranes. Mol. Vis. 2010, 16:1098-1107.
4. Abu El-Asrar A.M., Struyf S., Verbeke H., Van Damme J., Geboes K. Circulating bone-marrow-derived endothelial precursor cells contribute to neovascularization in diabetic epiretinal membranes. Acta Ophthalmol. 2011, 89:222-228.
5. Abu El-Asrar A.M., Van den Steen P.E., Al-Amro S.A., Missotten L., Opdenakker G., Geboes K. Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders. Int. Ophthalmol. 2007, 27:11-22.
6. Abu-El-Asrar A.M., Dralands L., Missotten L., Al-Jadaan I.A., Geboes K. Expression of apoptosis markers in the retinas of human subjects with diabetes. Invest Ophthalmol. Vis. Sci. 2004, 45:2760-2766.
7. Agrawal S., Anderson P., Durbeej M., van Rooijen N., Ivars F., Opdenakker G., Sorokin L.M. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J.Exp. Med. 2006, 203:1007-1019.
8. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., Witzenbichler B., Schatteman G., Isner J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
9. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell. Biol. 2000, 2:737-744.
10. Boivin D., Labbe D., Fontaine N., Lamy S., Beaulieu E., Gingras D., Beliveau R. The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases. Biochemistry 2009, 48:3998-4007.
11. Brown D., Hamdi H., Bahri S., Kenney M.C. Characterization of an endogenous metalloproteinase in human vitreous. Curr. Eye Res. 1994, 13:639-647.
12. Burns J.M., Summers B.C., Wang Y., Melikian A., Berahovich R., Miao Z., Penfold M.E., Sunshine M.J., Littman D.R., Kuo C.J., Wei K., McMaster B.E., Wright K., Howard M.C., Schall T.J. Anovel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J.Exp. Med. 2006, 203:2201-2213.
13. Butler J.M., Guthrie S.M., Koc M., Afzal A., Caballero S., Brooks H.L., Mames R.N., Segal M.S., Grant M.B., Scott E.W. SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J.Clin. Invest. 2005, 115:86-93.
14. Carmeliet P., Jain R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug. Discov. 2011, 10:417-427.
15. Cauwe B., Opdenakker G. Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit. Rev. Biochem Mol. Biol. 2010, 45:351-423.
16. Cauwe B., Van den Steen P.E., Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 2007, 42:113-185.
17. Clark I.M., Swingler T.E., Sampieri C.L., Edwards D.R. The regulation of matrix metalloproteinases and their inhibitors. Int. J. Biochem Cell. Biol. 2008, 40:1362-1378.
18. Coral K., Angayarkanni N., Madhavan J., Bharathselvi M., Ramakrishnan S., Nandi K., Rishi P., Kasinathan N., Krishnakumar S. Lysyl oxidase activity in the ocular tissues and the role of LOX in proliferative diabetic retinopathy and rhegmatogenous retinal detachment. Invest. Ophthalmol. Vis. Sci. 2008, 49:4746-4752.
19. Corbeil D., Roper K., Fargeas C.A., Joester A., Huttner W.B. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2001, 2:82-91.
20. Corbeil D., Roper K., Hellwig A., Tavian M., Miraglia S., Watt S.M., Simmons P.J., Peault B., Buck D.W., Huttner W.B. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J.Biol. Chem. 2000, 275:5512-5520.
21. Corbeil D., Roper K., Weigmann A., Huttner W.B. AC133 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family?. Blood 1998, 91:2625-2626.
22. Deryugina E.I., Quigley J.P. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim. Biophys. Acta 2010, 1803:103-120.
23. Descamps F.J., Martens E., Ballaux F., Geboes K., Opdenakker G. Invivo activation of gelatinase B/MMP-9 by trypsin in acute pancreatitis is a permissive factor in streptozotocin-induced diabetes. J.Pathol. 2004, 204:555-561.
24. Descamps F.J., Martens E., Kangave D., Struyf S., Geboes K., Van Damme J., Opdenakker G., Abu El-Asrar A.M. The activated form of gelatinase B/matrix metalloproteinase-9 is associated with diabetic vitreous hemorrhage. Exp. Eye Res. 2006, 83:401-407.
25. Descamps F.J., Martens E., Proost P., Starckx S., Van den Steen P.E., Van Damme J., Opdenakker G. Gelatinase B/matrix metalloproteinase-9 provokes cataract by cleaving lens betaB1 crystallin. FASEB J. 2005, 19:29-35.
26. Descamps F.J., Van den Steen P.E., Martens E., Ballaux F., Geboes K., Opdenakker G. Gelatinase B is diabetogenic in acute and chronic pancreatitis by cleaving insulin. FASEB J. 2003, 17:887-889.
27. Dubois B., Masure S., Hurtenbach U., Paemen L., Heremans H., van den Oord J., Sciot R., Meinhardt T., Hämmerling G., Opdenakker G., Arnold B. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J.Clin. Invest. 1999, 104:1507-1515.
28. Dubreuil V., Marzesco A.M., Corbeil D., Huttner W.B., Wilsch-Brauninger M. Midbody and primary cilium of neural progenitors release extracellular membrane particles enriched in the stem cell marker prominin-1. J.Cell. Biol. 2007, 176:483-495.
29. Ebrahem Q., Chaurasia S.S., Vasanji A., Qi J.H., Klenotic P.A., Cutler A., Asosingh K., Erzurum S., Anand-Apte B. Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization invivo. Am. J. Pathol. 2010, 176:496-503.
30. Fargeas C.A., Florek M., Huttner W.B., Corbeil D. Characterization of prominin-2, a new member of the prominin family of pentaspan membrane glycoproteins. J.Biol. Chem. 2003, 278:8586-8596.
31. Fargeas C.A., Huttner W.B., Corbeil D. Nomenclature of prominin-1 (CD133) splice variants - an update. Tissue Antigens 2007, 69:602-606.
32. Giebel S.J., Menicucci G., McGuire P.G., Das A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab. Invest. 2005, 85:597-607.
33. Gurudev N., Florek M., Corbeil D., Knust E. Prominent role of prominin in the retina. Adv. Exp. Med. Biol. 2013, 777:55-71.
34. Han Z., Anderson D.W., Papermaster D.S. Prominin-1 localizes to the open rims of outer segment lamellae in Xenopus laevis rod and cone photoreceptors. Invest. Ophthalmol. Vis. Sci. 2012, 53:361-373.
35. Head B.P., Patel H.H., Insel P.A. Interaction of membrane/lipid rafts with the cytoskeleton: impact on signaling and function: membrane/lipid rafts, mediators of cytoskeletal arrangement and cell signaling. Biochim. Biophys. Acta 2014, 1838:532-545.
36. Heissig B., Hattori K., Dias S., Friedrich M., Ferris B., Hackett N.R., Crystal R.G., Besmer P., Lyden D., Moore M.A., Werb Z., Rafii S. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002, 109:625-637.
37. Heissig B., Werb Z., Rafii S., Hattori K. Role of c-kit/Kit ligand signaling in regulating vasculogenesis. Thromb. Haemost. 2003, 90:570-576.
38. Hermansen S.K., Christensen K.G., Jensen S.S., Kristensen B.W. Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J.Histochem. Cytochem. 2011, 59:391-407.
39. Hollborn M., Stathopoulos C., Steffen A., Wiedemann P., Kohen L., Bringmann A. Positive feedback regulation between MMP-9 and VEGF in human RPE cells. Invest. Ophthalmol. Vis. Sci. 2007, 48:4360-4367.
40. Hu J., Van den Steen P.E., Sang Q.X., Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug. Discov. 2007, 6:480-498.
41. Ishida S., Usui T., Yamashiro K., Kaji Y., Ahmed E., Carrasquillo K.G., Amano S., Hida T., Oguchi Y., Adamis A.P. VEGF164 is proinflammatory in the diabetic retina. Invest. Ophthalmol. Vis. Sci. 2003, 44:2155-2162.
42. Ishizaki E., Takai S., Ueki M., Maeno T., Maruichi M., Sugiyama T., Oku H., Ikeda T., Miyazaki M. Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. Am. J. Ophthalmol. 2006, 141:129-134.
43. Jaszai J., Fargeas C.A., Florek M., Huttner W.B., Corbeil D. Focus on molecules: prominin-1 (CD133). Exp. Eye Res. 2007, 85:585-586.
44. Jaszai J., Fargeas C.A., Graupner S., Tanaka E.M., Brand M., Huttner W.B., Corbeil D. Distinct and conserved prominin-1/CD133-positive retinal cell populations identified across species. PLoS One 2011, 6:e17590.
45. Jaszai J., Janich P., Farkas L.M., Fargeas C.A., Huttner W.B., Corbeil D. Differential expression of Prominin-1 (CD133) and Prominin-2 in major cephalic exocrine glands of adult mice. Histochem. Cell. Biol. 2007, 128:409-419.
46. Jin M., Kashiwagi K., Iizuka Y., Tanaka Y., Imai M., Tsukahara S. Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 2001, 21:28-33.
47. Jonas J.B., Jonas R.A., Neumaier M., Findeisen P. Cytokine concentration in aqueous humor of eyes with diabetic macular edema. Retina 2012, 32:2150-2157.
48. Joussen A.M., Poulaki V., Le M.L., Koizumi K., Esser C., Janicki H., Schraermeyer U., Kociok N., Fauser S., Kirchhof B., Kern T.S., Adamis A.P. Acentral role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004, 18:1450-1452.
49. Kemper K., Sprick M.R., de B.M., Scopelliti A., Vermeulen L., Hoek M., Zeilstra J., Pals S.T., Mehmet H., Stassi G., Medema J.P. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 2010, 70:719-729.
50. Karbanová J., Missol-Kolka E., Fonseca A.V., Lorra C., Janich P., Hollerová H., Jászai J., Ehrmann J., Kolár Z., Liebers C., Arl S., Subrtová D., Freund D., Mokry J., Huttner W.B., Corbeil D. The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. J. Histochem. Cytochem. 2008, 56:977-993.
51. Kim J., Kim C.S., Lee Y.M., Jo K., Shin S.D., Kim J.S. Methylglyoxal induces hyperpermeability of the blood-retinal barrier via the loss of tight junction proteins and the activation of matrix metalloproteinases. Gr. Arch. Clin. Exp. Ophthalmol. 2012, 250:691-697.
52. Kolaczkowska E., Arnold B., Opdenakker G. Gelatinase B/MMP-9 as an inflammatory marker enzyme in mouse zymosan peritonitis: comparison of phase-specific and cell-specific production by mast cells, macrophages and neutrophils. Immunobiology 2008, 213:109-124.
53. Korol A., Pino G., Dwivedi D., Robertson J.V., Deschamps P.A., West-Mays J.A. Matrix metalloproteinase-9 null mice are resistant to TGF-beta-induced anterior subcapsular cataract formation. Am. J. Pathol. 2014, 184:2001-2012.
54. Kosano H., Okano T., Katsura Y., Noritake M., Kado S., Matsuoka T., Nishigori H. ProMMP-9 (92 kDa gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy. Life Sci. 1999, 64:2307-2315.
55. Kowluru R.A., Mohammad G., dos Santos J.M., Zhong Q. Abrogation of MMP-9 gene protects against the development of retinopathy in diabetic mice by preventing mitochondrial damage. Diabetes 2011, 60:3023-3033.
56. Krüger A., Kates R.E., Edwards D.R. Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochim. Biophys. Acta 2010, 1803:95-102.
57. Li B., Sharpe E.E., Maupin A.B., Teleron A.A., Pyle A.L., Carmeliet P., Young P.P. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J. 2006, 20:1495-1497.
58. Li T.S., Hamano K., Nishida M., Hayashi M., Ito H., Mikamo A., Matsuzaki M. CD117+ stem cells play a key role in therapeutic angiogenesis induced by bone marrow cell implantation. Am. J. Physiol. Heart Circ. Physiol. 2003, 285:H931-H937.
59. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
60. Lopez-Otin C., Overall C.M. Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell. Biol. 2002, 3:509-519.
61. Loukovaara S., Robciuc A., Holopainen J.M., Lehti K., Pessi T., Liinamaa J., Kukkonen K.T., Jauhiainen M., Koli K., Keski-Oja J., Immonen I. Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFbeta1 in diabetic eyes undergoing vitrectomy. Acta Ophthalmol. 2013, 91:531-539.
62. Mali R.S., Cheng M., Chintala S.K. Intravitreous injection of a membrane depolarization agent causes retinal degeneration via matrix metalloproteinase-9. Invest. Ophthalmol. Vis. Sci. 2005, 46:2125-2132.
63. Manabe S., Gu Z., Lipton S.A. Activation of matrix metalloproteinase-9 via neuronal nitric oxide synthase contributes to NMDA-induced retinal ganglion cell death. Invest. Ophthalmol. Vis. Sci. 2005, 46:4747-4753.
64. Mannello F. Effects of blood collection methods on gelatin zymography of matrix metalloproteinases. Clin. Chem. 2003, 49:339-340.
65. Mannello F., Tonti G.A., Tanus-Santos J.E., Gerlach R.F. Silicate increases the release of MMP-9 forms in peripheral blood: why gelatin zymography differs significantly in citrate plasma and serum obtained with or without clot activators. Clin. Chem. 2007, 53:1981-1982.
66. Martens E., Leyssen A., Van Aelst I., Fiten P., Piccard H., Hu J., Descamps F.J., Van den Steen P.E., Proost P., Van Damme J., Liuzzi G.M., Riccio P., Polverini E., Opdenakker G. Amonoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains. Biochim. Biophys. Acta 2007, 1770:178-186.
67. Marzesco A.M., Janich P., Wilsch-Brauninger M., Dubreuil V., Langenfeld K., Corbeil D., Huttner W.B. Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. J.Cell. Sci. 2005, 118:2849-2858.
68. Matsui J., Wakabayashi T., Asada M., Yoshimatsu K., Okada M. Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells. J.Biol. Chem. 2004, 279:18600-18607.
69. Maw M.A., Corbeil D., Koch J., Hellwig A., Wilson-Wheeler J.C., Bridges R.J., Kumaramanickavel G., John S., Nancarrow D., Roper K., Weigmann A., Huttner W.B., Denton M.J. Aframeshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. Hum. Mol. Genet. 2000, 9:27-34.
70. Miraglia S., Godfrey W., Buck D. Aresponse to AC133 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family?. Blood 1998, 91:4390-4391.
71. Miraglia S., Godfrey W., Yin A.H., Atkins K., Warnke R., Holden J.T., Bray R.A., Waller E.K., Buck D.W. Anovel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997, 90:5013-5021.
72. Miyamoto K., Khosrof S., Bursell S.E., Rohan R., Murata T., Clermont A.C., Aiello L.P., Ogura Y., Adamis A.P. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:10836-10841.
73. Mohammad G., Kowluru R.A. Diabetic retinopathy and signaling mechanism for activation of matrix metalloproteinase-9. J.Cell. Physiol. 2012, 227:1052-1061.
74. Mohammad G., Siddiquei M.M., Othman A., Al-Shabrawey M., Abu El-Asrar A.M. High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina. Exp. Eye Res. 2013, 107:101-109.
75. Morgunova E., Tuuttila A., Bergmann U., Isupov M., Lindqvist Y., Schneider G., Tryggvason K. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science 1999, 284:1667-1670.
76. Navaratna D., McGuire P.G., Menicucci G., Das A. Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes 2007, 56:2380-2387.
77. Noda K., Ishida S., Inoue M., Obata K., Oguchi Y., Okada Y., Ikeda E. Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2003, 44:2163-2170.
78. Ollivier F.J., Gilger B.C., Barrie K.P., Kallberg M.E., Plummer C.E., O'Reilly S., Gelatt K.N., Brooks D.E. Proteinases of the cornea and preocular tear film. Vet. Ophthalmol. 2007, 10:199-206.
79. Opdenakker G., Van den Steen P.E., Laureys G., Hunninck K., Arnold B. Neutralizing antibodies in gene-defective hosts. Trends Immunol. 2003, 24:94-100.
80. Overall C.M., Dean R.A. Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev. 2006, 25:69-75.
81. Paemen L., Martens E., Masure S., Opdenakker G. Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity. Eur. J. Biochem. 1995, 234:759-765.
82. Patel J.I., Tombran-Tink J., Hykin P.G., Gregor Z.J., Cree I.A. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: implications for structural differences in macular profiles. Exp. Eye Res. 2006, 82:798-806.
83. Permanyer J., Navarro R., Friedman J., Pomares E., Castro-Navarro J., Marfany G., Swaroop A., Gonzalez-Duarte R. Autosomal recessive retinitis pigmentosa with early macular affectation caused by premature truncation in PROM1. Invest. Ophthalmol. Vis. Sci. 2010, 51:2656-2663.
84. Piccard H., Van den Steen P.E., Opdenakker G. Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins. J.Leukoc. Biol. 2007, 81:870-892.
85. Pras E., Abu A., Rotenstreich Y., Avni I., Reish O., Morad Y., Reznik-Wolf H., Pras E. Cone-rod dystrophy and a frameshift mutation in the PROM1 gene. Mol. Vis. 2009, 15:1709-1716.
86. Prudova A., Auf dem Keller U., Butler G.S., Overall C.M. Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics. Mol. Cell. Proteom. 2010, 9:894-911.
87. Roper K., Corbeil D., Huttner W.B. Retention of prominin in microvilli reveals distinct cholesterol-based lipid micro-domains in the apical plasma membrane. Nat. Cell. Biol. 2000, 2:582-592.
88. Salzmann J., Limb G.A., Khaw P.T., Gregor Z.J., Webster L., Chignell A.H., Charteris D.G. Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy. Br. J. Ophthalmol. 2000, 84:1091-1096.
89. Sanchez M.C., Luna J.D., Barcelona P.F., Gramajo A.L., Juarez P.C., Riera C.M., Chiabrando G.A. Effect of retinal laser photocoagulation on the activity of metalloproteinases and the alpha(2)-macroglobulin proteolytic state in the vitreous of eyes with proliferative diabetic retinopathy. Exp. Eye Res. 2007, 85:644-650.
90. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell. Dev. Biol. 2001, 17:463-516.
91. Takahashi H., Akiba K., Noguchi T., Ohmura T., Takahashi R., Ezure Y., Ohara K., Zieske J.D. Matrix metalloproteinase activity is enhanced during corneal wound repair in high glucose condition. Curr. Eye Res. 2000, 21:608-615.
92. Van den Steen P.E., Dubois B., Nelissen I., Rudd P.M., Dwek R.A., Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol. 2002, 37:375-536.
93. Van den Steen P.E., Proost P., Brand D.D., Kang A.H., Van Damme J., Opdenakker G. Generation of glycosylated remnant epitopes from human collagen type II by gelatinase B. Biochemistry 2004, 43:10809-10816.
94. Van Geest R.J., Klaassen I., Lesnik-Oberstein S.Y., Tan H.S., Mura M., Goldschmeding R., Van Noorden C.J., Schlingemann R.O. Vitreous TIMP-1 levels associate with neovascularization and TGF-beta2 levels but not with fibrosis in the clinical course of proliferative diabetic retinopathy. J.Cell. Commun. Signal 2013, 7:1-9.
95. Vandooren J., Geurts N., Martens E., Van den Steen P.E., Opdenakker G. Zymography methods for visualizing hydrolytic enzymes. Nat. Methods 2013, 10:211-220.
96. Vandooren J., Van den Steen P.E., Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit. Rev. Biochem. Mol. Biol. 2013, 48:222-272.
97. Vu T.H., Shipley J.M., Bergers G., Berger J.E., Helms J.A., Hanahan D., Shapiro S.D., Senior R.M., Werb Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998, 93:411-422.
98. Walter D.H., Haendeler J., Reinhold J., Rochwalsky U., Seeger F., Honold J., Hoffmann J., Urbich C., Lehmann R., Arenzana-Seisdesdos F., Aicher A., Heeschen C., Fichtlscherer S., Zeiher A.M., Dimmeler S. Impaired CXCR4 signaling contributes to the reduced neovascularization capacity of endothelial progenitor cells from patients with coronary artery disease. Circ. Res. 2005, 97:1142-1151.
99. Wang H., Keiser J.A. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ. Res. 1998, 83:832-840.
100. Weigmann A., Corbeil D., Hellwig A., Huttner W.B. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:12425-12430.
101. Yamaguchi J., Kusano K.F., Masuo O., Kawamoto A., Silver M., Murasawa S., Bosch-Marce M., Masuda H., Losordo D.W., Isner J.M., Asahara T. Stromal cell-derived factor-1 effects on exvivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 2003, 107:1322-1328.
102. Yang Z., Chen Y., Lillo C., Chien J., Yu Z., Michaelides M., Klein M., Howes K.A., Li Y., Kaminoh Y., Chen H., Zhao C., Chen Y., Al-Sheikh Y.T., Karan G., Corbeil D., Escher P., Kamaya S., Li C., Johnson S., Frederick J.M., Zhao Y., Wang C., Cameron D.J., Huttner W.B., Schorderet D.F., Munier F.L., Moore A.T., Birch D.G., Baehr W., Hunt D.M., Williams D.S., Zhang K. Mutant prominin 1 found in patients with macular degeneration disrupts photoreceptor disk morphogenesis in mice. J.Clin. Invest. 2008, 118:2908-2916.
103. Yildirim N., Sahin A., Erol N., Kara S., Uslu S., Topbas S. The relationship between plasma MMP-9 and TIMP-2 levels and intraocular pressure elevation in diabetic patients after intravitreal triamcinolone injection. J.Glaucoma 2008, 17:253-256.
104. Zacchigna S., Oh H., Wilsch-Brauninger M., Missol-Kolka E., Jaszai J., Jansen S., Tanimoto N., Tonagel F., Seeliger M., Huttner W.B., Corbeil D., Dewerchin M., Vinckier S., Moons L., Carmeliet P. Loss of the cholesterol-binding protein prominin-1/CD133 causes disk dysmorphogenesis and photoreceptor degeneration. J.Neurosci. 2009, 29:2297-2308.
105. Zhang Q., Haleem R., Cai X., Wang Z. Identification and characterization of a novel testosterone-regulated prominin-like gene in the rat ventral prostate. Endocrinology 2002, 143:4788-4796.
106. Zhang Q., Zulfiqar F., Xiao X., Riazuddin S.A., Ahmad Z., Caruso R., MacDonald I., Sieving P., Riazuddin S., Hejtmancik J.F. Severe retinitis pigmentosa mapped to 4p15 and associated with a novel mutation in the PROM1 gene. Hum. Genet. 2007, 122:293-299.